ArabFinance: Al Ahly Pharos Securities Brokerage Research has set the fair value (FV) of Ibnsina Pharma (ISPH) at EGP 4.80 per share, with a recommendation of “Overweight”, the research firm noted in a report.

It is worth noting that the company’s consolidated net profit attributable to the holding company stood at EGP 314.72 million in 2021, up from EGP 224.66 million in 2020.

Meanwhile, the company’s standalone net profit after tax grew to EGP 315.65 million in 2021 from EGP 224.78 million in 2020.

Ibnsina is an Egypt-based pharmaceutical distribution company, with a diversified portfolio of pharmaceutical products from over 350 Egyptian and multinational companies to more than 35,000 customers including pharmacies, hospitals, retail outlets, and wholesalers.